JP2004533450A - 心臓障害および代謝障害のための甲状腺ホルモン受容体アンタゴニストｉｉ - Google Patents

心臓障害および代謝障害のための甲状腺ホルモン受容体アンタゴニストｉｉ Download PDF

Info

Publication number
JP2004533450A
JP2004533450A JP2002589436A JP2002589436A JP2004533450A JP 2004533450 A JP2004533450 A JP 2004533450A JP 2002589436 A JP2002589436 A JP 2002589436A JP 2002589436 A JP2002589436 A JP 2002589436A JP 2004533450 A JP2004533450 A JP 2004533450A
Authority
JP
Japan
Prior art keywords
dibromo
phenyl
amino
propionate
triethylammonium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002589436A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004533450A5 (enExample
Inventor
マルム，ジョアン
ブラント，ピーター
エドビンソン，カリン
エリクソン，トーマス
ゴルドン，サンドラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karo Healthcare AB
Original Assignee
Karo Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karo Pharma AB filed Critical Karo Pharma AB
Publication of JP2004533450A publication Critical patent/JP2004533450A/ja
Publication of JP2004533450A5 publication Critical patent/JP2004533450A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP2002589436A 2001-05-15 2002-04-15 心臓障害および代謝障害のための甲状腺ホルモン受容体アンタゴニストｉｉ Pending JP2004533450A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0111861.1A GB0111861D0 (en) 2001-05-15 2001-05-15 Novel compounds
PCT/EP2002/004193 WO2002092550A1 (en) 2001-05-15 2002-04-15 Thyroid hormone receptor antagonists for cardiac and metabolic disorders ii

Publications (2)

Publication Number Publication Date
JP2004533450A true JP2004533450A (ja) 2004-11-04
JP2004533450A5 JP2004533450A5 (enExample) 2005-12-22

Family

ID=9914678

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002589436A Pending JP2004533450A (ja) 2001-05-15 2002-04-15 心臓障害および代謝障害のための甲状腺ホルモン受容体アンタゴニストｉｉ

Country Status (11)

Country Link
US (1) US7319096B2 (enExample)
EP (1) EP1387825A1 (enExample)
JP (1) JP2004533450A (enExample)
KR (1) KR20040017812A (enExample)
CN (1) CN1275938C (enExample)
AU (1) AU2002310850B2 (enExample)
CA (1) CA2446747A1 (enExample)
DE (1) DE02735262T1 (enExample)
GB (1) GB0111861D0 (enExample)
IL (1) IL158671A0 (enExample)
WO (1) WO2002092550A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003066574A1 (ja) * 2002-02-07 2005-05-26 仁 遠藤 芳香族アミノ酸誘導体及び医薬組成物

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0208384D0 (en) * 2002-04-11 2002-05-22 Karobio Ab Novel compounds
WO2004052861A1 (ja) * 2002-12-12 2004-06-24 Kowa Co., Ltd. ヒドロキシアルキル環状ジアミン化合物
WO2005051298A2 (en) * 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
EP1690538A4 (en) * 2003-12-02 2009-02-25 Shionogi & Co ISOXAZOLE DERIVATIVE AGONISTIC ACTION AGAINST PEROXISOM PROLIFERATOR ACTIVATED RECEPTOR
GB0405033D0 (en) * 2004-03-05 2004-04-07 Karobio Ab Novel pharmaceutical compositions
GB0406380D0 (en) * 2004-03-22 2004-04-21 Karobio Ab Novel pharmaceutical compositions
DE102005003632A1 (de) 2005-01-20 2006-08-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Katheter für die transvaskuläre Implantation von Herzklappenprothesen
US20090028925A1 (en) * 2005-05-26 2009-01-29 Erion Mark D Novel Phosphinic Acid-Containing Thyromimetics
JP2008542301A (ja) 2005-05-26 2008-11-27 メタバシス・セラピューティクス・インコーポレイテッド 脂肪性肝疾患の処置のための甲状腺ホルモン様薬剤
US20070213813A1 (en) 2005-12-22 2007-09-13 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
US7896915B2 (en) 2007-04-13 2011-03-01 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
ES2903231T3 (es) 2008-02-26 2022-03-31 Jenavalve Tech Inc Stent para el posicionamiento y anclaje de una prótesis valvular en un sitio de implantación en el corazón de un paciente
US9044318B2 (en) 2008-02-26 2015-06-02 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis
US10856978B2 (en) 2010-05-20 2020-12-08 Jenavalve Technology, Inc. Catheter system
WO2011147849A1 (en) 2010-05-25 2011-12-01 Jenavalve Technology Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
JP6563394B2 (ja) 2013-08-30 2019-08-21 イェーナヴァルヴ テクノロジー インコーポレイテッド 人工弁のための径方向に折り畳み自在のフレーム及び当該フレームを製造するための方法
JP6829692B2 (ja) 2015-03-20 2021-02-10 イェーナヴァルヴ テクノロジー インコーポレイテッド 心臓弁プロテーゼ送出システム及び導入体シースにより心臓弁プロテーゼを送出するための方法
EP4403138A3 (en) 2015-05-01 2024-10-09 JenaValve Technology, Inc. Device and method with reduced pacemaker rate in heart valve replacement
CN109475419B (zh) 2016-05-13 2021-11-09 耶拿阀门科技股份有限公司 用于通过引导鞘和装载系统来递送心脏瓣膜假体的心脏瓣膜假体递送系统和方法
EP3541395A4 (en) 2016-11-21 2020-07-01 Viking Therapeutics, Inc. GLYCOGENOSIS TREATMENT METHODS
US11197754B2 (en) 2017-01-27 2021-12-14 Jenavalve Technology, Inc. Heart valve mimicry
EP3634426A4 (en) 2017-06-05 2021-04-07 Viking Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF FIBROSIS
KR20200138283A (ko) 2018-03-22 2020-12-09 바이킹 테라퓨틱스 인코포레이티드 결정질 형태, 및 결정질 형태의 화합물을 제조하는 방법
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
JP2025538294A (ja) 2022-11-09 2025-11-27 イエナバルブ テクノロジー インク 拡張可能なインプラントの順次展開のためのカテーテルシステム

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9713739D0 (en) * 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
GB9816935D0 (en) * 1998-08-05 1998-09-30 Karobio Ab Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders
GB9927056D0 (en) 1999-11-17 2000-01-12 Karobio Ab Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003066574A1 (ja) * 2002-02-07 2005-05-26 仁 遠藤 芳香族アミノ酸誘導体及び医薬組成物
JP4705756B2 (ja) * 2002-02-07 2011-06-22 仁 遠藤 芳香族アミノ酸誘導体及び医薬組成物

Also Published As

Publication number Publication date
AU2002310850B2 (en) 2005-11-10
CA2446747A1 (en) 2002-11-21
DE02735262T1 (de) 2004-07-08
KR20040017812A (ko) 2004-02-27
CN1509267A (zh) 2004-06-30
US20040220147A1 (en) 2004-11-04
IL158671A0 (en) 2004-05-12
US7319096B2 (en) 2008-01-15
EP1387825A1 (en) 2004-02-11
GB0111861D0 (en) 2001-07-04
WO2002092550A1 (en) 2002-11-21
CN1275938C (zh) 2006-09-20

Similar Documents

Publication Publication Date Title
US7319163B2 (en) Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
JP2004533450A (ja) 心臓障害および代謝障害のための甲状腺ホルモン受容体アンタゴニストｉｉ
AU2002310850A1 (en) Thyroid hormone receptor antagonists for cardiac and metabolic disorders II
US20050171104A1 (en) Novel thyroid receptor ligands
JP6215890B2 (ja) 縮合環類似体の抗線維症剤
JP2003508380A (ja) スルホニルカルボキサミド誘導体、その調製方法および医薬としてのその使用
AU2002237298B2 (en) Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands
US7279593B2 (en) Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
AU2002237298A1 (en) Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands
AU2002331145A1 (en) Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
JP2003508381A (ja) 高脂血症の予防または治療用薬剤の製造のためのビススルホンアミドの使用
CN1332921C (zh) 治疗心脏和代谢紊乱的主环取代的甲状腺受体拮抗物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090609

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091124